Given that both EGF and Wnt signaling pathways can positively regulate CHD6 activity, it lends credence to the possibility that targeting EGFR-ERK activation (Cetuximab) plus Wnt signaling (Wnt inhibitor) might have a better synergistic effect in treating CHD6-high CRC. The gene discussed is CHD6; the disease is colorectal carcinoma.